These findings enabled the introduction of anti-PD-1 (pembrolizumab and nivolumab) and anti-PD-L1 (atezolizumab and durvalumab) monoclonal antibodies for the treatment of NSCLC patients. This evidence concerns the gene CD274 and non-small cell lung carcinoma.